Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccination and Local Immunomodulation in Advanced Metastatic Melanoma
NCT01191034Phase 2Terminated
- Start
- Aug 2010
- Primary completion
- Aug 2012
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MAGE-3.A1 peptide, NA-17.A2 in melanoma. Started Aug 2010; status: terminated.
02
Drugs
MAGE-3.A1 peptideNA-17.A2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01191034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191034.